+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07791160

Observational Study of Acoramidis in Adults with Wild-Type or Variant Transthyretin Amyloid Cardiomyopathy

Led by Bayer · Updated on 2026-09-15

500

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Transthyretin amyloid cardiomyopathy ATTR-CM is a progressive heart condition caused by the buildup of an abnormal protein called transthyretin in the heart, which can impair heart function and worsen symptoms over time. Acoramidis is a medicine approved for adults with wild-type or hereditary ATTR-CM. While its benefits have been shown in clinical trials, more information is needed about how it is used and how patients fare in everyday medical care. This observational study in France follows patients receiving acoramidis as part of their usual medical treatment. Participants take acoramidis orally at a dose of 712 mg twice daily. No experimental treatments or extra medical procedures are required beyond standard care. The study collects data directly from hospitals and from the Healthcare European Amyloidosis Registry to understand patient experiences and treatment use. Participants will be followed for 12 months after starting acoramidis. During this time, researchers will assess quality of life, daily functioning, and overall well-being at 3, 6, 9, and 12 months using patient-completed questionnaires. Additional information about patient characteristics, treatment patterns, safety, and tolerability will also be collected. This research aims to improve understanding and care of people living with ATTR-CM.

CONDITIONS

Brief Title

Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy

Research Team

B

Bayer Clinical Trials Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here